AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Amplia Therapeutics Limited (ASX:ATX) has set its 2026 annual general meeting for 28 August 2026, where shareholders will vote on key governance issues including director re-elections, a substantial $450,000 increase in non-executive director fees, and approval for issuing zero-exercise-price options to senior management. The company will also seek shareholder consent for expanded equity issuance capacity and present its financial statements for the fiscal year ended 31 March 2026.
Key Highlights
- Amplia Therapeutics Limited (ATX) will conduct its 2026 AGM on 28 August 2026 at Grant Thornton, Melbourne, as an in-person only meeting.
- Shareholders will consider increasing the non-executive directors' fee pool by $450,000, raising the annual limit from $300,000 to $750,000.
- The company proposes issuing a total of 2,730,629 zero-exercise-price options to five directors, including 687,772 options to Managing Director Dr Christopher Burns.
- Amplia requests approval for an additional 10% placement capacity under ASX Listing Rule 7.1A and will present its financial and auditor reports for the year ended 31 March 2026.
Details of Amplia Therapeutics’ 2026 AGM Venue and Format
Amplia Therapeutics Limited announced its 2026 annual general meeting will be held on Friday, 28 August 2026, starting at 10:30am at Grant Thornton’s Melbourne office located at Collins Square, Level 22, Tower 5, 727 Collins Street, Victoria. The meeting will be conducted exclusively as a physical event with no online or hybrid participation options, requiring shareholders to attend in person to engage directly.
The agenda includes ten items covering routine financial reporting, director elections, significant governance proposals, and director remuneration matters. Shareholders will vote on ordinary and special resolutions, with some requiring a three-quarter majority. The company advises shareholders to carefully review the notice of meeting and explanatory materials and consult financial advisors if uncertain about voting decisions.
Proposal to Increase Non-Executive Directors’ Fee Pool by 150%
A major agenda item is Resolution 5, seeking shareholder approval to raise the annual aggregate fees for non-executive directors by $450,000, increasing the cap from $300,000 to $750,000. This 150% increase indicates plans to expand the board or adjust remuneration to attract or retain experienced non-executive directors amid Amplia’s growth and strategic complexity.
This special resolution complies with ASX Listing Rule 10.17 and includes voting exclusions preventing key management personnel and their close associates from voting in favour. While the company’s public summary does not detail the rationale, the accompanying explanatory statement provides full context for the fee pool increase.
Director Re-Elections and New Appointment on the 2026 Ballot
Shareholders will vote on two director-related resolutions. Resolution 2 proposes re-electing Dr Robert Peach, who retires under the company constitution and stands for re-election, requiring ordinary resolution approval. Resolution 3 seeks election of Mr Brett Carter, also retiring by rotation and standing for election, requiring ordinary resolution approval. Voting exclusions apply to related party votes for these resolutions.
The simultaneous re-election and election suggest potential board restructuring or replacement of departing directors. Detailed biographies and qualifications for both candidates are included in the explanatory materials.
Issuance of Zero-Exercise-Price Options to Board Members
Amplia requests shareholder approval to issue zero-exercise-price options to all five current or incoming directors as part of its equity-based remuneration strategy. These issuances require ASX Listing Rule 10.14 approval, with voting exclusions preventing recipients and their associates from voting on their own option grants.
Resolution 6 covers 687,772 options for Managing Director Dr Christopher Burns. Resolutions 7 to 10 propose 642,857 options for Non-Executive Chair Ms Jane Bell, and 500,000 options each for non-executive directors Dr Robert Peach, Dr Warwick Tong, and Mr Brett Carter. The total options proposed amount to 2,730,629. The public summary does not specify vesting conditions or performance metrics.
Request for Additional 10% Placement Capacity Under ASX Listing Rule 7.1A
Resolution 4 seeks shareholder approval for an additional 10% placement facility under Listing Rule 7.1A, allowing Amplia to issue equity securities without prior shareholder approval within prescribed limits. This special resolution provides the company with greater capital management flexibility to support future financing or strategic transactions.
Voting exclusions apply to prevent parties who may benefit materially from the placement facility from voting in favour, safeguarding shareholder interests. This request aligns with typical capital requirements for therapeutic development companies needing timely access to funding.
Presentation of Financial and Remuneration Reports for FY 2026
Item 1 on the agenda is the receipt of Amplia’s Financial Report, Directors’ Report, and Auditor’s Report for the year ended 31 March 2026, presented for shareholder consideration without requiring a vote. These reports are accessible via the company’s investor relations website at ampliatx.com/reports.
Resolution 1 seeks adoption of the Remuneration Report for FY 2026 by ordinary resolution. This non-binding vote allows shareholders to express views on senior management and director pay practices. Voting exclusions apply to key management personnel and their close associates. A "no" vote of 25% or higher could trigger further governance reviews.
Robust Voting Exclusions and Compliance with Governance Standards
Amplia enforces strict voting exclusions across multiple resolutions to comply with the Corporations Act and ASX Listing Rules, preventing conflicts of interest and ensuring voting integrity. Key management personnel and related parties are excluded from voting on remuneration and option-related resolutions (Resolutions 1, 5, 6–10). Additional exclusions apply to the placement facility and fee pool increase resolutions.
Strategic Implications of Board Changes and Remuneration Enhancements
The proposed director elections, fee pool expansion, and significant option grants indicate a strategic realignment of Amplia’s board and incentive framework. The 150% increase in non-executive director fees suggests a focus on attracting higher-calibre independent directors with relevant biotech expertise. The zero-exercise-price options, especially the large allocation to Managing Director Dr Christopher Burns, align management incentives with shareholder value creation, fostering long-term performance alignment.
While the announcement does not disclose specific performance hurdles for the options, the broad participation of all board members highlights a cohesive leadership incentive approach.
Contextual Overview: Governance and Capital Needs in Therapeutic Development Sector
Operating in the capital-intensive biopharmaceutical sector, Amplia’s governance and capital proposals reflect industry norms requiring experienced boards with scientific, regulatory, and commercial expertise. The fee increase and expanded equity capacity are consistent with attracting skilled directors and enabling timely capital raises for clinical development and commercialisation.
The additional 10% placement facility enhances Amplia’s ability to secure funding efficiently, critical in a sector where development timelines and regulatory milestones demand agile capital management. These governance and capital measures signal management’s confidence in advancing strategic objectives over the coming years.
